Gerald Reischl Selected Research

fluoromisonidazole

1/2022	Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT.
7/2020	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy.
12/2019	Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic 18F-FMISO PET for Head and Neck Cancer Radiotherapy.
12/2019	Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis.
2/2019	2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction, 18F-Labeling and Preclinical PET Imaging.
11/2017	Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
11/2017	Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer.
6/2017	Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients.
1/2017	In Vivo Hypoxia PET Imaging Quantifies the Severity of Arthritic Joint Inflammation in Line with Overexpression of Hypoxia-Inducible Factor and Enhanced Reactive Oxygen Species Generation.
1/2017	Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gerald Reischl Research Topics

Disease

31	Neoplasms (Cancer) 01/2022 - 01/2005
18	Hypoxia (Hypoxemia) 01/2022 - 01/2005
7	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022 - 02/2005
5	Prostatic Neoplasms (Prostate Cancer) 10/2019 - 04/2009
5	Inflammation (Inflammations) 01/2019 - 03/2013
5	Carcinoma (Carcinomatosis) 12/2016 - 11/2011
3	Neuroblastoma 01/2022 - 10/2016
3	Rheumatoid Arthritis 12/2019 - 01/2017
3	Neoplasm Metastasis (Metastasis) 01/2019 - 02/2009
3	Squamous Cell Carcinoma of Head and Neck 11/2017 - 01/2015
3	Autoimmune Diseases (Autoimmune Disease) 01/2017 - 02/2014
3	Alzheimer Disease (Alzheimer's Disease) 12/2014 - 02/2008
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022 - 01/2019
2	Body Weight (Weight, Body) 01/2021 - 04/2013
2	Arthritis (Polyarthritis) 12/2019 - 05/2012
2	Experimental Arthritis 12/2019 - 01/2013
2	Breast Neoplasms (Breast Cancer) 01/2019 - 01/2016
2	Hypersensitivity (Allergy) 01/2019 - 01/2015
2	Yersinia Infections 03/2016 - 01/2016
2	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2012 - 03/2008
2	Parkinson Disease (Parkinson's Disease) 03/2008 - 02/2008
1	Pheochromocytoma 01/2022
1	Sarcoma (Soft Tissue Sarcoma) 01/2022
1	Parathyroid Neoplasms (Parathyroid Neoplasm) 04/2021
1	Pneumonia (Pneumonitis) 01/2019
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2019
1	Melanoma (Melanoma, Malignant) 01/2019
1	Hemorrhagic Stroke 01/2017
1	Hemorrhage 01/2017
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2017
1	Alcoholism (Alcohol Abuse) 01/2017

Drug/Important Bio-Agent (IBA)

14	fluoromisonidazoleIBA 01/2022 - 01/2005
10	fluoroazomycin arabinosideIBA 02/2019 - 01/2005
5	Biomarkers (Surrogate Marker)IBA 12/2016 - 04/2009
5	Oxygen (Dioxygen)IBA 12/2016 - 01/2005
4	azomycinIBA 02/2019 - 01/2007
4	LigandsIBA 01/2017 - 02/2008
4	AntibodiesIBA 10/2016 - 09/2010
4	alovudineIBA 05/2016 - 06/2010
3	AntigensIBA 01/2017 - 04/2009
3	NitroimidazolesIBA 01/2017 - 01/2005
3	Amyloid beta-PeptidesIBA 09/2011 - 02/2008
3	carbogenIBA 04/2008 - 01/2005
2	Hormones (Hormone)IBA 01/2021 - 10/2011
2	salicylhydroxamic acid (SHAM)IBA 12/2019 - 03/2007
2	Therapeutic UsesIBA 12/2019 - 05/2016
2	gallium 68 PSMA-11IBA 10/2019 - 01/2017
2	CollagenIBA 01/2019 - 10/2008
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 02/2008
2	Biological ProductsIBA 11/2017 - 04/2008
2	Monoclonal AntibodiesIBA 10/2016 - 09/2010
2	1- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononaneIBA 05/2016 - 03/2016
2	Glucose (Dextrose)FDA LinkGeneric 08/2015 - 04/2013
2	Ketamine FDA LinkGeneric 01/2015 - 07/2013
2	Isoflurane FDA LinkGeneric 01/2015 - 07/2013
2	Xylazine (Xylazin)IBA 01/2015 - 07/2013
2	Choline (Choline Chloride)IBA 03/2013 - 10/2011
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 04/2009 - 02/2009
2	Peptides (Polypeptides)IBA 02/2009 - 04/2008
2	Integrin alphaVbeta3IBA 02/2009 - 04/2008
2	alpha-SynucleinIBA 03/2008 - 02/2008
1	dinutuximabIBA 01/2022
1	GangliosidesIBA 01/2022
1	monoethylcholineIBA 04/2021
1	Insulin (Novolin)FDA Link 01/2021
1	LN950IBA 12/2019
1	skepinone-LIBA 12/2019
1	AutoantibodiesIBA 12/2019
1	Glucose-6-Phosphate Isomerase (Phosphoglucose Isomerase)IBA 12/2019
1	Mitogen-Activated Protein KinasesIBA 12/2019
1	p38 Mitogen-Activated Protein KinasesIBA 12/2019
1	NucleosidesIBA 02/2019
1	Nucleoside Transport Proteins (Nucleoside Transporter)IBA 02/2019
1	SugarsIBA 02/2019
1	LipopolysaccharidesIBA 01/2019
1	3-Iodobenzylguanidine (Iobenguane)IBA 01/2019
1	IsomerasesIBA 01/2019
1	Fibronectins (Fibronectin)IBA 01/2019
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2019
1	CationsIBA 01/2019
1	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 01/2019
1	CatecholaminesIBA 01/2019
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 01/2019
1	platelet membrane glycoprotein VIIBA 01/2019
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2019
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 11/2017
1	pimonidazoleIBA 01/2017
1	Glial Fibrillary Acidic ProteinIBA 01/2017
1	PSMA-11IBA 01/2017
1	Serum Response FactorIBA 01/2017
1	IronIBA 01/2017
1	L 012IBA 01/2017
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017

Therapy/Procedure

8	Therapeutics 12/2019 - 06/2002
7	Radiotherapy 01/2022 - 02/2005
3	Chemoradiotherapy 01/2022 - 01/2017
3	Immunotherapy 01/2019 - 02/2014
3	Drug Therapy (Chemotherapy) 11/2017 - 06/2010
2	Radioimmunotherapy 01/2022 - 04/2009
2	Anesthesia 01/2015 - 07/2013